Fluidx Medical disclosed study results examining extent of vessel filling using the GPX Embolic Device compared to microspheres, a common treatment for many types of tumors. Embolization is a procedure in which arterial or venous blood supply to an organ, malformation, aneurysm, bleed, tumor, and/or other abnormal area of issue is blocked. Metal coils, microsphere particles, and/or liquids are common embolics delivered through small 0.5mm – 1.5mm outer diameter 100 – 150cm long catheters. “GPX is demonstrating deep distal vessel…

Scientists at the Max Planck Institute for Intelligent Systems in Germany have developed tumor-targeting microrobots using bacteria. The team exploited the tendency of bacteria to naturally gravitate towards areas of low oxygen and low ph, which both tend to occur in the vicinity of a tumor. Once near the tumor, the bacteria aggravate the immune system, with the tumor experiencing some collateral damage. However, the researchers also turbocharged the ability of the bacteria to target the tumor by binding magnetic…

Researchers at MIT have created a microparticle vaccine that can provide booster doses automatically. The hollow microparticles resemble a coffee cup with a lid, and are made using poly(lactic-co-glycolic acid), otherwise known as PLGA. The polymer breaks down over time in the body, releasing the contents of the hollow particles. By changing the composition of the polymer and the chemical groups attached to it, the researchers can tweak the release time, allowing them to deliver an assortment of particles that…

Researchers at the University of Waterloo in Canada created a soft robotic sleeve to treat lymphedema. Lymphedema involves uid accumulation in tissues because of damage to the lymph system. This wearable sleeve combines a microuidic controller and soft robotic components that apply compression to the arm to reduce and control uid accumulation. The small components avoid the need for a stationary pump to inate the sleeve and allow for tetherless use during regular activities. Lymphedema often strikes breast cancer patients,…

Researchers at the Technical University of Munich in Germany have developed a new protein therapeutic against SARS-CoV-2. Unlike previously developed antibody therapies and vaccines, the virus is very unlikely to be able to circumvent this latest technology through mutation, as it is based on the viral target site in the body, the ACE2 receptor. The technology consists of the ACE2 protein, which the researchers have fused with a fragment of a human antibody to ensure that it remains stable for…